Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site

Bioorganic and Medicinal Chemistry

Volumn 6, Issue 5, 1998, Pages 595-604

  Takashiro, Eiji ^a   Watanabe, Takashi ^a   Nitta, Tamayo ^a   Kasuya, Atsushi ^a   Miyamoto, Shuichi ^a   Ozawa, Yuji ^a   Yagi, Ryuichi ^a   Nishigaki, Takashi ^a   Shibayama, Takahiro ^a   Nakagawa, Akihiko ^a   Iwamoto, Aikichi ^b   Yabe, Yuichiro ^a  

^a DAIICHI SANKYO CO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PHENYLBUTYRATES; SPECTRUM ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

CANIS FAMILIARIS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031746876     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(98)00004-2     Document Type: Article

References (29)

1. (a) Mitsuya H.; Yarchoan, R.; Broder, S. Science 1990, 249, 1533.
2. (b) Yarchoan, R.; Mitsuya, H.; Broder, S. Trends in Pharmacol. Sci. 1993, 14, 196 and references cited therein.
3. (c) Hellen, C. U. T.; Kräusslich, H. H-G.; Wimmer, E. Biochemstry 1989, 28, 9881.
4. (d) Rich, D. H. J. Med. Chem. 1985, 85, 263.
5. For excellent reviews on HIV-1 protease inhibitors, see: (a) Wlodawer, A.; Erickson, J. W. Annu. Rev. Biochem. 1993, 62, 543.
6. (b) West, M. L.; Fairlie, D. P. Trends Pep. Sci. 1995, 16, 67.
7. (c) Meek, T. D. J. Enzyme Inhibition 1992, 6, 65.
8. For AHPBA, see: Mimoto, T.; Imai, L; Kisanuki, S.; Enomoto, H.; Hattori, N.; Akaji, K.; Kiso, Y. Chem. Pharm. Bull. 1992, 40, 2251 and references cited therein.
9. Barry, M.; Gibbons, S.; Back, D.; Mulcahy, F. Clin. Pharmacokinet. 1997, 32, 194.
10. (a) Sakurai, M.; Higashida, S.; Sugano, M.; Kornai, T.; Yagi, R.; Ozawa, Y.; Handa, K; Nishigaki, T.; Yabe, Y. Bioorg. Med. Chem. 1994, 2, 807.
11. (b) Komai, T.; Higashida, S.; Sakurai, M.; Nitta, T.; Kasuya, A.; Miyamoto, S.; Yagi, R.; Ozawa, Y.; Handa, H.; Mohri, H.; Yasuoka, A.; Oka, S.; Nishigaki, T.; Kimura, S.; Shimada, K.; Yabe, Y. Bioorg. Med. Chem. 1996, 4, 1365.
12. (a) Ghosh, A. K.; Thompson, W. L.; McKee, S. R.; Duong, T. T.; Lyle, T. A.; Chen, J. C.; Darke, P. L.; Zugay, J. A.; Emilio, E. A.; Schleif, W. A.; Huff, J. R.; Anderson, P. S. J. Med. Chem. 1993, 36, 292.
13. (b) Ghosh, A. K.; Lee, H. Y.; Thompson, W. L.; Culberson, C.; Holloway, M. K.; McKee, S. R.; Munson, P. M.; Duong, T. T.; Smith, A. M.; Darke, P. L.; Zugay, J. A.; Emilio, E. A.; Scheif, W. A.; Huff, J. R.; Anderson, P. S. J. Med. Chem. 1994, 37, 1177.
14. (a) Randad, R. S.; Lubkowska, L.; Bhat, T. N.; Munshi, S.; Gulnik, S. V.; Yu, B.; Erickson, J. W. Bioorg. Med. Chem. Lett. 1995, 5, 1707.
15. (b) Kempf, D. L.; Flentge, C. A.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; Norbeck, D. W. Bioorg. Med. Chem. Lett. 1995, 5, 2725.
16. Kalish, V. L.; Tatlock, J. H.; Davis, II, J. R.; Kaldor, S. W.; Dressman, B. A.; Reich, S.; Pino, M.; Nyugen, D.; Appelt, K.; Musick, L.; Wu, B-W. Bioorg. Med. Chem. Lett. 1995, 5, 727.
17. Kaldor S. W.; Hammond, M.; Dressman, B. A.; Fritz, J. E.; Crowell, T. A.; Hermann, R. A. Bioorg. Med. Chem. Lett. 1994, 4, 1385.
18. Fleet, G. W. L; Gough, M. L.; Shing, T. K. M. Tetrahedron Lett. 1983, 24, 3661.
19. Houbion, J. A.; Miles, J. A.; Paton, J. A. Org. Prep. Proc. Int. 1979, 11, 27.
20. Mandell, L.; Caine, D.; Kilpatrick, G. E. J. Am. Chem. Soc. 1961, 83, 4457.
21. Richtzenhain, H. Chem. Ber. 1944, 1.
22. Lindgren, B. O.; Nilsson, T. Acta Chem. Scand. 1973, 27, 888.
23. Nicolaou, K. C.; Bunnage, M. E.; Kiode, K. J. Am. Chem. Soc. 1994, 116, 8402.
24. Comins, D. L.; Brown, J. D., J. Org. Chem. 1989, 54, 3730.
25. Ghosh, A. K.; Duong, T. T.; McKee, S. R.; Thompson, W. J. Tetrahedron Lett. 1992, 33, 2781.
26. Ghosh et al. reported that cyclic urethanes with 3S-configuration were more potent than ones with 3R-configuration (see Ref. 6).
27. The detailed computational studies will be reported elsewhere.
28. For structural water, see: Wang, Y.-X.; Freedberg, D. L.; Wingfield, P. T.; Stahl, S. L.; Kaufman, J. D.; Kiso, Y.; Bhat, T. N.; Erickson, J. W.; Torchia, D. A. J. Am. Chem. Soc. 1996, 118, 12287 and references cited therein.
29. The conclusion described by Kempf et al. was that ortho is not a suitable position for interaction with Asp 29 or 30 (see Ref. 7b). But the hydrogen bond interaction between the carbonyls and the ortho hydroxyl groups is presumed to be more important than aforesaid interaction.